Compare Johnson & Johnson (JNJ) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs KraneShares Electric Vehicles and Future Mobility — how do they compare? Johnson & Johnson trades at $260.73 (market cap $626.09B), while KraneShares Electric Vehicles and Future Mobility trades at $30.99. The key difference: Johnson & Johnson pays a 2.06% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and Johnson & Johnson is trading nearer its 52-week high, KraneShares Electric Vehicles and Future Mobility nearer its low. Which is the better fit depends on your goals.
| JNJ | KARS | |
|---|---|---|
Market Cap | $626.09B | — |
Volume | 6,156,228 | — |
Sector | Health | Sector/Thematic |
52-Week High | $267.24 | $38.01 |
52-Week Low | $172.78 | $25.59 |
Enterprise Value | $654.37B | — |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
KARS trades at $30.95, down 0.55% today, with a bullish technical signal driven by moving averages and oscillators, though the RSI_6 at 85.22 suggests overbought conditions. Support lies near $30, resistance at $31. Recent news highlights strong global EV sales growth, particularly in Europe and China, driven by high fuel prices and policy support, though U.S. adoption lags.
The outlook for KARS is supported by accelerating EV adoption globally, but risks include U.S. market hesitation, competitive pressures from Chinese automakers, and potential volatility from geopolitical events. Analyst sentiment is mixed, with technical indicators bullish but valuation metrics unavailable, requiring close monitoring of upcoming financial results for clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About KraneShares Electric Vehicles and Future Mobility
KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.
Read more on KARS →
